Avanos Medical (NYSE:AVNS – Get Rating) issued an update on its FY 2022 earnings guidance on Wednesday morning. The company provided EPS guidance of $1.55-$1.75 for the period, compared to the consensus EPS estimate of $1.64. The company issued revenue guidance of $830.00 million-$850.00 million, compared to the consensus revenue estimate of $842.09 million.
Shares of Avanos Medical stock opened at $25.36 on Wednesday. The firm has a market cap of $1.20 billion, a PE ratio of 66.74 and a beta of 0.87. The stock’s 50-day moving average price is $31.85. The company has a quick ratio of 1.93, a current ratio of 2.87 and a debt-to-equity ratio of 0.20. Avanos Medical has a 12-month low of $24.85 and a 12-month high of $45.42.
Avanos Medical (NYSE:AVNS – Get Rating) last posted its earnings results on Wednesday, May 4th. The company reported $0.26 earnings per share for the quarter, hitting the consensus estimate of $0.26. The company had revenue of $197.40 million for the quarter, compared to analyst estimates of $197.80 million. Avanos Medical had a net margin of 2.44% and a return on equity of 4.49%. The business’s revenue for the quarter was up 9.2% compared to the same quarter last year. During the same period last year, the business posted $0.23 earnings per share. On average, equities analysts predict that Avanos Medical will post 1.66 EPS for the current year.
Several institutional investors and hedge funds have recently modified their holdings of the stock. Norges Bank bought a new stake in Avanos Medical during the 4th quarter valued at $15,630,000. Morgan Stanley grew its holdings in shares of Avanos Medical by 256.9% during the second quarter. Morgan Stanley now owns 372,986 shares of the company’s stock valued at $13,565,000 after buying an additional 268,465 shares during the last quarter. Millennium Management LLC increased its position in shares of Avanos Medical by 177.1% during the fourth quarter. Millennium Management LLC now owns 314,192 shares of the company’s stock worth $10,893,000 after acquiring an additional 200,792 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of Avanos Medical by 0.4% in the 4th quarter. Legal & General Group Plc now owns 194,149 shares of the company’s stock worth $6,731,000 after acquiring an additional 692 shares during the last quarter. Finally, Parametric Portfolio Associates LLC lifted its position in Avanos Medical by 17.0% in the 4th quarter. Parametric Portfolio Associates LLC now owns 127,366 shares of the company’s stock valued at $4,416,000 after acquiring an additional 18,538 shares in the last quarter. Institutional investors own 92.71% of the company’s stock.
About Avanos Medical (Get Rating)
Avanos Medical, Inc, a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands.
- Get a free copy of the StockNews.com research report on Avanos Medical (AVNS)
- Fifth Third Bancorp Stock Bestows Opportunity
- 3 Reasons Why Hostess Brands Could Be a Sweet Addition to Your Watchlist
- 3 Online Education Stocks Investors Should Study
- XPO Logistics Is A Logical Choice For Investors
- If PetMeds Is A Good Buy There Will Be A Better Signal
Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.